First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC

First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC
The Phase 3 trial ELEVATE UC 52 evaluating Arena Pharmaceuticals’ investigational therapy etrasimod for patients with moderately to severely active ulcerative colitis has dosed its first patient. "We are pleased to enroll the first patient in the ELEVATE UC trial, supporting etrasimod's potential as an important future therapy for ulcerative colitis," Darshan Anandu, MD, of G.I. Specialists of Houston, said in a press release. ”With 60-80% of patients either not receiving or failing on the current standard of care, there is a clear and significant need for innovative options, especially orally delivered treatments,” Anandu said. Etrasimod works by modulating the selective sphingosine 1 phosphate receptor, which is involved in immune cell recruitment. By modulating the receptor, the treatment reduces the number of immune cells reaching tissues, thus diminishing immune response and inflammation and alleviating symptoms. The ELEVATE UC 52 trial (NCT03945188), currently recruiting participants, will evaluate the safety and efficacy of etrasimod treatment in moderate or severe cases of ulcerative colitis compared to a placebo. After a 28-day screening period, patients will receive etrasimod as a 2 mg once-daily oral capsule for 12 weeks
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *